Dimerix Limited (ASX: DXB)

Dimerix Limited (ASX: DXB) is discovering and developing important new drug therapies for major unmet medical needs identified using a proprietary cell-based drug discovery platform. www.dimerix.com

Dimerix ASX DXB DMX-700 Chronic Obstructive Pulmonary Disease COPD drug pipeline

Dimerix targets ‘important new drug discovery’ in the treatment of chronic obstructive pulmonary disease

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has announced plans to target the development of what it calls...
Dimerix ASX DXB orphan drug designation EU Europe DMX-200 kidney Dr Nina Webster

Dimerix receives orphan drug designation in Europe for DMX-200

Drug development company Dimerix (ASX: DXB) has confirmed that the European Commission (EC) has approved its DMX-200...
Proteomics International Dimerix ASX PIQ DXB kidney disease

Proteomics International and Dimerix join forces to combat kidney disease

Medical technology company Proteomics International (ASX: PIQ) has teamed up with biotech stock Dimerix (ASX: DXB) to...
Dimerix ASX DXB positive kidney disease trial shares rally

Dimerix shares rally on positive results from kidney disease trial

Dimerix Limited (ASX: DXB) shares have rallied over 36% as the company reported positive safety and efficacy data...